Prognostic value of serum and ascites levels of estradiol, FSH, LH and prolactin in ovarian cancer

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1575-1578

  Chen, Frank Chih Kang ^a   Oskay Özcelik, Guelten ^a   Bühling, Kai J ^a   Köpstein, Uta ^a   Mentze, Monika ^a   Lichtenegger, Werner ^a   Sehouli, Jalid ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Estradiol; FSH; LH; Ovarian cancer; Prolactin

Indexed keywords

ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; PROLACTIN;

ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; INTRAOPERATIVE PERIOD; MAJOR CLINICAL STUDY; OVARY CANCER; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ASCITES; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; PROLACTIN;

EID: 67650085135     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 57: 43-66, 2007.
2. Bristow RE, Tomacruz RF, DK Armstrong, EL Trimble and Montz FJ: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 20: 1248-1259, 2002. (Pubitemid 34177431)
3. Holschneider CH and Berek JS: Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19: 3-10, 2000. (Pubitemid 30439309)
4. Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC and Comstock GW: Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 274: 1926-1930, 1995. (Pubitemid 26003062)
5. Moorman PG, Cahngaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, Berchuck A and Schildkraut JM: Risk Factors for Ovarian Cancer in Premenopausal and Postmenopausal Women. Am J Epidemiol 167: 1059-1069, 2008. (Pubitemid 351601240)
6. Fathalla MF: Incessant ovulation - a factor in ovarian neoplasia? Lancet 17: 163, 1971.
7. Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A and Hughes C: Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet. Gynecol 88: 554-559, 1996. (Pubitemid 26326017)
8. Parrott JA, Doraiswamy V, Kim G, Mosher R and Skinner MK: Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 172: 213-222, 2001. (Pubitemid 32098413)
9. Syed V, Ulinski G, Mok SC, Yiu GK and Ho SM: Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 61: 6768-6776, 2001. (Pubitemid 32896499)
10. Choi KC, Kang SK, Tai CJ, Auersperg N and Leung PC: Follicle-stimulating hormone activates mitogen-activated protein kinase in preneoplastic and neoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 87: 2245-2253, 2002. (Pubitemid 34521516)
11. Ji Q, Liu PI, Chen PK and Aoyama C: Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells. Int J Cancer 12: 803-814, 2004. (Pubitemid 39435265)
12. Pavelka JC, Brown RS, Karlan BY, Cass I, Leuchter RS, Lagasse LD and Li AJ: Effect of obesity on survival in epithelial ovarian cancer. Cancer 107: 1520-1524, 2006. (Pubitemid 44546912)
13. Zheng H, Kavanagh JJ, Hu W, Liao Q and Fu S: Hormonal therapy in ovarian cancer. Int J Gynecol Cancer 17: 325-338, 2007
14. Williams CJ: Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev CD001034, 2001
15. Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, Williams AR Nafussi AA, Rye T, Rye R, Stewart M, McCurdy J, Mano M, Reed N, McMahon T, Vasey P, Gabra H and Langdon SP: Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 13: 3617-3622, 2007. (Pubitemid 46955124)
16. Choi KC, Kang SK, Tai CJ, Auersperg N and Leung PC: Estradiol up-regulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells. Endocrinology 142: 2351-2360, 2001. (Pubitemid 32473090)
17. Walker G, MacLeod K, Williams AR, Cameron DA, Smyth JF and Langdon SP: Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer. Gynecol Oncol 106: 461-468, 2007. (Pubitemid 47302473)
18. Sun P, Sehouli J, Denkert C, Mustea A, Könsgen D, Koch I, Wie L and Lichtenegger W: Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells. J Mol Med 83: 457-467, 2005. (Pubitemid 40922168)
19. Asai-Sato M, Nagashima Y, Miyagi E, Sato K, Ohta I, Vonderhaar BK and Hirahara F: Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment. Int J Cancer 115: 539-544, 2005. (Pubitemid 40656710)